Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Insights - The company achieved a revenue of 294 million yuan in the first half of 2025, representing a year-on-year increase of 75.41%. However, it reported a loss of 132 million yuan, narrowing by 12.57% year-on-year, with an adjusted net loss of 108 million yuan, which is a 7.18% increase in loss compared to the previous year [1][2]. Financial Performance - Gross margin for the first half of 2025 was 35.93%, down by 23.25 percentage points, primarily due to amortization of Alcon-related product licenses and changes in the business model of certain products. The company managed to control the growth rate of operating expenses effectively [2]. - Revenue from ophthalmic products reached 285 million yuan, up 89.77%, driven by significant growth in the revenue from collaborative pipelines and licensed products [3]. - The company is in a critical phase of turning around its losses, with expectations for improved profitability driven by the resumption of supply for OT401 and the ramp-up of new products [2][4]. Product Pipeline and Development - The product matrix is continuously improving, with key products advancing rapidly. Notably, OT1001 has received NMPA approval and is the only FDA-approved anti-allergy ophthalmic drug for patients aged two and above [3]. - OT703 has been included in a real-world data application pilot program, and OT802 has received CDE approval for its Phase III clinical trial, expected to start in early 2026 [3]. Revenue and Profit Forecast - The company is projected to generate revenues of 820 million yuan, 1.192 billion yuan, and 1.556 billion yuan for 2025, 2026, and 2027, respectively. The expected net profit attributable to shareholders is forecasted to be -74 million yuan, 108 million yuan, and 277 million yuan for the same years [4][5].
欧康维视生物-B（01477）：营收持续高增，关注重磅管线进度